TriangleCIML-NK Cells (NCT07635056)
CIML-NK Cells trial for Neuroblastoma (NCT07635056). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged one through 39 with relapsed or refractory high-risk neuroblastoma and an available partly matched related donor. Disease must be measurable or otherwise evaluable.
The idea: donor natural killer cells are collected by apheresis, prepared with cytokines, and infused during dinutuximab-based treatment. Dinutuximab binds GD2 on tumor cells to recruit immune attack. Researchers test whether the cell product can be prepared and infused safely, tracking infusion reactions over 30 days.
This phase 2 study plans 20 patients. Christopher Dandoy leads at Cincinnati Children's, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.